Markus A. Rüegg

Professor of Neurobiology

Biozentrum / University of Basel

Markus A. Rüegg

Dr. Markus Rüegg is Professor for Neurobiology at the Biozentrum, University of Basel, Switzerland. He studied Biochemistry and Neurobiology in Zurich and Stanford and was co-founder and member of the management of MyoContract, now called Santhera Pharmaceuticals, a biotech company that dedicated to develop therapies for neuromuscular diseases.

Dr. Rüegg is an internationally recognized expert in neuromuscular research and has published numerous scientific papers in the field of neuromuscular research. In recent years, his work has also been devoted to the study of therapeutic interventions in mouse models for congenital muscular dystrophy. Dr. Rüegg is also partner of the network TREAT-NMD.

His main research interests are the molecular pathways involved in muscle wasting diseases in general. He has authored more than 70 publications in major journals such as Nature, Nat. Cell Biol., Neuron, J. Cell Biol., EMBO J. and is inventor on 4 patents. Invited speaker to EMBO and ENMC Workshops, Gordon Research Conferences, to the World Muscle Society and several additional major meetings in the filed. . Markus is a member of scientific panels of Muscular Dystrophy UK and Cure CMD and he is chairman of the scientific council of the Swiss Foundation for Research on Muscle Diseases (FSRMM).